Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Ups The Ante In Immunotherapy With CoStim Buy

This article was originally published in The Pink Sheet Daily

Executive Summary

The European pharma is increasing its stake in cancer immunotherapy with the acquisition of a start-up biotech that brings over late-stage assets against several targets.

You may also be interested in...



Deal Watch: Teva/Mylan/Perrigo Speculation Pushes Busy Celgene, AstraZeneca Offstage

AstraZeneca and its large-molecule affiliate MedImmune will partner with Celgene to develop anti-PD-LI immune checkpoint inhibitor MEDI4736. MedImmune also signed combination trial agreements with Juno and Immunocore, while Celgene arranged to buy Quanticel and Mesoblast.

J.P. Morgan Notebook, Jan. 12: Biogen, Novartis, Celgene

Welcome to “The Pink Sheet” DAILY’s round-up of news and notes from the first day of the 2015 J.P. Morgan Healthcare Conference in San Francisco.

Start-Up Quarterly Statistics, Q1 2014

Start-up companies raised $1.18 billion during the first quarter of 2014, up $2.8 million from last quarter’s total. Cancer was the leading therapy area involved in alliances.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

GB150348

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel